FindTrial
Sign In

Regorafenib (BAY 73-4506)

DRUG6 trials

Sponsors

UNC Lineberger Comprehensive Cancer Center, Zhejiang University, Beijing Friendship Hospital, The Methodist Hospital Research Institute, Sergey Orlov, MD

Conditions

Colorectal Cancer MetastaticColorectal NeoplasmsHepato Cellular Carcinoma (HCC)Hepatocellular CarcinomaMCRCMetastatic Colorectal Cancer (CRC)Metastatic Colorectal Cancer (mCRC)

Phase 1

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
RecruitingNCT05155189
Zhejiang UniversityHepatocellular Carcinoma
Start: 2022-02-21End: 2041-05-01Target: 72Updated: 2026-01-21

Phase 2

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
CompletedNCT01298570
UNC Lineberger Comprehensive Cancer CenterColorectal Cancer Metastatic
Start: 2011-04-07End: 2020-10-02Updated: 2021-01-06
Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer
RecruitingNCT06829355
Beijing Friendship HospitalMCRC
Start: 2025-02-11End: 2027-12-31Target: 52Updated: 2025-02-17
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
RecruitingNCT06887218
The Methodist Hospital Research InstituteMetastatic Colorectal Cancer (CRC)
Start: 2025-05-08End: 2029-12-31Target: 57Updated: 2025-08-27
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
RecruitingNCT06949982
Sergey Orlov, MDColorectal Neoplasms, Metastatic Colorectal Cancer (mCRC)
Start: 2025-03-17End: 2027-10-31Target: 60Updated: 2025-05-04
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
Not yet recruitingNCT07328009
Fudan UniversityHepato Cellular Carcinoma (HCC)
Start: 2026-01-25End: 2029-01-15Target: 350Updated: 2026-01-21

Related Papers

Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2024-06-0139 citations
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
International Journal of Molecular Sciences2023-12-19
KDR genetic predictor of toxicities induced by sorafenib and regorafenib.
2022-04-285 citations